- Home
- NRO vs IPHA Comparison
NRO vs IPHA Comparison
Compare NRO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- IPHA
- Stock Information
- Founded
- NRO 2003
- IPHA 1999
- Country
- NRO United States
- IPHA France
- Employees
- NRO N/A
- IPHA N/A
- Industry
- NRO Finance/Investors Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- IPHA Health Care
- Exchange
- NRO Nasdaq
- IPHA Nasdaq
- Market Cap
- NRO 189.8M
- IPHA 191.0M
- IPO Year
- NRO N/A
- IPHA 2019
- Fundamental
- Price
- NRO $4.02
- IPHA $2.28
- Analyst Decision
- NRO
- IPHA Strong Buy
- Analyst Count
- NRO 0
- IPHA 1
- Target Price
- NRO N/A
- IPHA $11.50
- AVG Volume (30 Days)
- NRO 239.4K
- IPHA 5.5K
- Earning Date
- NRO 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- NRO 11.41%
- IPHA N/A
- EPS Growth
- NRO N/A
- IPHA N/A
- EPS
- NRO N/A
- IPHA N/A
- Revenue
- NRO N/A
- IPHA $36,202,722.00
- Revenue This Year
- NRO N/A
- IPHA N/A
- Revenue Next Year
- NRO N/A
- IPHA $105.84
- P/E Ratio
- NRO N/A
- IPHA N/A
- Revenue Growth
- NRO N/A
- IPHA 6.88
- 52 Week Low
- NRO $2.51
- IPHA $1.81
- 52 Week High
- NRO $3.45
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- NRO 75.35
- IPHA 50.55
- Support Level
- NRO $3.80
- IPHA $2.27
- Resistance Level
- NRO $4.03
- IPHA $2.41
- Average True Range (ATR)
- NRO 0.05
- IPHA 0.11
- MACD
- NRO 0.00
- IPHA -0.00
- Stochastic Oscillator
- NRO 95.65
- IPHA 52.94
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.